Production of another COVID-19 vaccine to begin in weeks

Production of another potential vaccine against COVID-19 will begin in weeks, its developers Sanofi and GlaxoSmithKline said Thursday that they are launching a major trial involving 35,000 adult volunteers in the United States, Asia, Africa and Latin America.

The study will test candidate formulas for the vaccine against the original coronavirus that spreads from Wuhan, China, and against the variant seen for the first time in South Africa, pharmaceutical companies said.

If the process is successful, regulators could approve vaccination for use in the last three months of the year, the drugs said in a statement.

“Manufacturing will begin in the coming weeks to allow quick access to the vaccine if it is to be approved,” they said.

His statement quoted Thomas Triomphe, who directs vaccine research and development at Sanofi Pasteur, as saying: “We are encouraged to see the first vaccinations being started in such an important, crucial Phase 3 study.”

Earlier this month, companies said their vaccination candidate triggered strong immune responses in all adult age groups in preliminary tests after a previous return, raising optimism that the vaccine could join the fight. against the pandemic this year.

After two doses of the vaccination candidate, participants showed antibodies in line with those found in people who have recovered from the disease, according to the results of the previous, smaller trial.

Regulators have already authorized a number of COVID-19 vaccines, although experts say they need more than public health authorities around the world are running to vaccinate their inhabitants amid a pandemic that has already killed more than 3.4 million people and that caused economic devastation.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button